Page last updated: 2024-12-07

hydroxypropyl-gamma-cyclodextrin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID2733545
MeSH IDM0152340

Synonyms (1)

Synonym
hydroxypropyl-gamma-cyclodextrin

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Poor oral bioavailability of three experimental compounds, 1-III, observed in animals has been attributed to the low intrinsic solubility."( Effects of inclusion complexation on the transepithelial transport of a lipophilic substance in vitro.
Chen, FJ; Cho, MJ; Huczek, DL, 1995
)
0.29
" The rate and extent of nasal bioavailability of buserelin were remarkably increased by coadministration of oleic acid and HP-beta-CyD, compared with the sole use of the enhancer."( Enhanced nasal delivery of luteinizing hormone releasing hormone agonist buserelin by oleic acid solubilized and stabilized in hydroxypropyl-beta-cyclodextrin.
Abe, K; Irie, T; Uekama, K, 1995
)
0.29
"The object of this study was to enhance the solubility, dissolution rate, and oral bioavailability of rutin by complexation with 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CyD)."( Improvement of solubility and oral bioavailability of rutin by complexation with 2-hydroxypropyl-beta-cyclodextrin.
Arima, H; Hirayama, F; Horikawa, T; Miyake, K; Noda, S; Sumiyoshi, H; Uekama, K; Yamamoto, M, 2000
)
0.31
"To explore the use of cyclodextrins (CD) to form inclusion complexes with beta-lapachone (beta-lap) to overcome solubility and bioavailability problems previously noted with this drug."( Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes.
Beman, M; Boothman, DA; Bornmann, WG; Bruening, A; Gao, J; Nasongkla, N; Ray, D; Wiedmann, AF, 2003
)
0.32
" Biologic activity and bioavailability of beta-lap inclusion complexes were investigated by in vitro cytotoxicity studies with MCF-7 cells and by in vivo lethality studies with C57Blk/6 mice (18-20 g)."( Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes.
Beman, M; Boothman, DA; Bornmann, WG; Bruening, A; Gao, J; Nasongkla, N; Ray, D; Wiedmann, AF, 2003
)
0.32
" The results of the study indicate that CPLX shows improved dissolution properties and a higher relative oral bioavailability compared with PHYS and MICO."( Oral bioavailability in pigs of a miconazole/hydroxypropyl-gamma-cyclodextrin/L-tartaric acid inclusion complex produced by supercritical carbon dioxide processing.
Barillaro, V; Delattre, L; Evrard, B; Piell, G, 2005
)
0.33
" It was shown that HPγCD curcumin demonstrated higher bioavailability in the biofilms compared to curcumin, without affecting the subcellular uptake."( Exploring photoinactivation of microbial biofilms using laser scanning microscopy and confined 2-photon excitation.
Ericson, MB; Farewell, A; Graf, FE; Thomsen, H, 2018
)
0.48
"It can be stated that the innovative PR-containing compositions are suitable for producing mucoadhesive, properly preserved aqueous ophthalmic solutions with increased bioavailability attributes."( Development of prednisolone-containing eye drop formulations by cyclodextrin complexation and antimicrobial, mucoadhesive biopolymer.
Aigner, Z; Bíró, T; Budai-Szűcs, M; Csányi, E; Csóka, I; Facskó, A; Horvát, G; Szabó-Révész, P; Urbán, E, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" This was done to evaluate potential degradation and thereby biological conversion of the cyclodextrins if dosed orally, as the intestinal tract contains α-amylase for digestive purposes."( In vitro investigations of α-amylase mediated hydrolysis of cyclodextrins in the presence of ibuprofen, flurbiprofen, or benzo[a]pyrene.
Holm, R; Jørgensen, EB; Larsen, KL; Lumholdt, LR, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (85)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's13 (15.29)18.2507
2000's33 (38.82)29.6817
2010's35 (41.18)24.3611
2020's4 (4.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other84 (97.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]